@Article{biocell.2022.015390,
AUTHOR = {YUANYUAN JIA, XIAONA MA, XIURUI YAN, JING XUE, TINGTING YANG, XUEYUN LIANG, XIAOMING LIU},
TITLE = {Identification of tumorigenic risk genes in human placenta-derived mesenchymal stem cells treated with 3-methylcholanthrene},
JOURNAL = {BIOCELL},
VOLUME = {46},
YEAR = {2022},
NUMBER = {2},
PAGES = {479--493},
URL = {http://www.techscience.com/biocell/v46n2/45104},
ISSN = {1667-5746},
ABSTRACT = {Mesenchymal stem cells (MSCs) capable of tumour topotaxis have been served as cellular vehicles to deliver
anti-tumour agents. As cellular components of the tumour microenvironment, MSCs also affect tumour progression.
However, the tumour transformation-related genes of MSCs remain unclear since either tumorigenic or tumour
suppressor effects within these cells have been researched. Hence, we aimed to identify potential biomarkers indicative
of tumorigenic risk by RNA-seq analysis of human placenta tissue-derived MSCs (hPTMSCs) exposed to the
carcinogenic agent, 3-methylcholanthrene (3-MC). Twenty-nine tumour transformation-related genes and three
pluripotency-related genes were appraised as differentially expressed genes (DEGs) in hPTMSCs. Overexpression of
<i>sfrp1</i> led to reduced cell viability, migration, and colony formation in A549. In contrast, the overexpression of <i>ptgs2</i>
exerted the opposite effect. These results indicate that A549 cells with high <i>ptgs2</i> expression but low <i>sfrp1</i> expression
may have a more potential tumorigenic capacity. Taken together, this study suggests that <i>ptgs2</i> and <i>sfrp1</i> may be
tumorigenic risk genes.},
DOI = {10.32604/biocell.2022.015390}
}